Mean platelet volume (MPV) is a biomarker of platelet activity and elevations in MPV have been seen in the setting of acute CV events. The aim of this study is to assess whether increases in MPV during acute CV events is observed in patients with NAFLD. Methods: A retrospective case control study of 104 patients with NAFLD who had cardiovascular events (CE) and 104 NAFLD patients (matched by age, gender and BMI) without cardiovascular events (non-CE) was performed.
Demographics, CV risk factors, laboratory data, and medications were collected. Included CV events were myocardial infarction/unstable angina (n=59), coronary artery bypass graft (n=36), stroke/transient ischemic attack/peripheral vascular disease (n = 12) and congestive heart failure (n=9). MPV’s were collected at the initial
Selleck MK-8669 time of the study (To)，at the time of the CV event (TCE）(or equivalent time period in the non-CE group) and at the end of follow up (Tf). To assess liver severity, the AST platelet ratio index (APRI) defined by (AST/upper limit normal AST/platelets X 100) was calculated. The Framingham risk score (FRS) was calculated to assess CV risk prior to the events. Statistical analysis was performed using student’s T test, Pearson’s chi squared see more and Mann Whitney U tests. Results: Demographics included a mean age of 56 ± 8 years (yr) with a majority of white ethnicity (CE, n= 85 versus non-CE, n=76), an average 上海皓元 BMI of 31.8 ± 5.1 and an average time to follow up 9.5 ± 2.7 yr. No difference in liver severity as assessed by APRI was noted between the groups (0.34 ± 0.19 in CE and 0.36 ± 0.17 in non-CE group, p= 0.47). The CE group had higher CV risk calculated by the FRS (24 ± 11.6%) compared to the non-CE group (18 ±12%) (p=0.0002). More patients in the CE group were exposed to aspirin and clopidogrel, p<0.0001. Average time from Tq to Tce was 4.9 ± 2.8 yr. Importantly, the absolute changes of MPV from T。to Tce and from T。to Tf [(MPV Tce -MPV T。) and (MPV Tf- MPV T。)] were statistically higher
in the CE group than in the non-CE group (table 1). Conclusion: The absolute change in the MPV level at the time of the CV event was higher in the CE group when compared to the non-CE group (0.54± 1.1 versus 0.21 ± 0.9, p=0.023). In addition, the increase in the MPV at study end was also higher in the CE group when compared to the non-CE group. Table 1 Change in MPV (TCĒ- T0) Change in MPV (TF-T0) CE group (Std dev) 0.54(1.1) 0.63(1.2) Non-CE group (Std dev) 0.21 (0.9) 0.26 (1.2) P value 0.023 0.02 Disclosures: The following people have nothing to disclose: Lisa Alvarez, Daisha Cipher, Rick A. Weideman, Geri Brown Background: Nonalcoholic fatty liver disease (NAFLD) typically occurs in persons who are overweight or obese and have metabolic risk factors such as diabetes, hypertension and hyperlipidemia.
- Gefitinib Iressa associated with platelet aggregation in vivo platelet
- Thus, gene therapy with platelet-directed FVIII expression is an
- We revealed that the SUVmax has the potency as a novel biomarker
- Comparing the ratio of activity per volume instead of total activ
- The biomarker advantage of pramipexole, however, did not translat